<DOC>
	<DOCNO>NCT00490776</DOCNO>
	<brief_summary>This study evaluate safety efficacy LBH589B adult patient refractory/resistant Cutaneous T-Cell Lymphoma prior HDAC inhibitor therapy .</brief_summary>
	<brief_title>Study Oral LBH589 Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent obtain prior screen procedure 2 . Age great equal 18 year old 3 . Patients biopsyconfirmed stage IBIVA mycosis fungoides Sézary syndrome . Patients SS bone marrow involvement also eligible . Patients transform CTCL eligible . 4 . Patients must treat HDAC inhibitor give treatment CTCL . Patients must disease progression follow treatment HDAC inhibitor . Patients also eligible inadequate response HDAC inhibitor define stable disease best response least 3 month therapy . Patients previously treat HDAC inhibitor also eligible experienced intolerance due adverse event . Exclusion criterion : 1 . Patients history visceral disease include CNS involvement ( i.e . stage IVB CTCL ) . Note , patient SS bone marrow involvement eligible . 2 . Impaired cardiac function 3 . Concomitant use drug risk cause torsades de pointes 4 . Patients receive chemotherapy investigational drug undergone major surgery ≤ 3 week prior start study drug recover side effect therapy 5 . Less 3 month since prior electron beam therapy 6 . Women pregnant breast feeding , woman childbearing potential ( WOCBP ) willing use double method contraception study 3 month end treatment . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
	<keyword>adult</keyword>
	<keyword>Mycosis Fungoides</keyword>
	<keyword>Sézary Syndrome</keyword>
	<keyword>CTCL</keyword>
</DOC>